Treatment of latent Mycobacterium tuberculosis infection in intravenous drug users co-infected with HIV

Francesca Sánchez, Montse Balagué, Patricia García de Olalla, José L. López Colomés, Vicente Martín, Rafael Guerrero, Andrés Marco, Joan A. Caylà

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: This clinical trial, carried out among injection drug users and the HIV-infected with tuberculin skin test ≥ 5 mm, aimed to evaluate the compliance and tolerability of two preventive strategies against tuberculosis (TB). Methods: Study protocol prospectively compares adherence to nine months of daily therapy with isoniazid (9H) versus two months of daily therapy with rifampin plus pyrazinamide (2RZ) administered randomly. All patients were concurrently admitted to a methadone maintenance programme. To assess toxicity, liver function was monitored monthly. Results: From 305 assessable patients, those in 2RZ arm showed better adherence (84% vs. 59%, p < 0.0001). Results on liver toxicity did not show significant differences between 9H and 2RZ (4.5% vs. 6.9%; odds ratio = 1.58, 95% confidence interval = 0.42-7.24). Conclusion: 2RZ should be considered an option to prevent TB in selected groups of patients infected with HIV, such as injection drug users on methadone treatment.

Original languageEnglish (US)
Pages (from-to)12-18
Number of pages7
JournalJournal of Infection Prevention
Volume11
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Keywords

  • HIV infection
  • Injection drug users
  • Latent tuberculosis infection
  • Methadone maintenance treatment
  • Short-course therapy

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health
  • Advanced and Specialized Nursing
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Treatment of latent Mycobacterium tuberculosis infection in intravenous drug users co-infected with HIV'. Together they form a unique fingerprint.

Cite this